Navigation Links
SEC Closes Investigation of PharmaNet Development Group and Recommends No Action
Date:10/5/2009

PRINCETON, N.J., Oct. 5 /PRNewswire/ -- PharmaNet Development Group, Inc., a leading provider of clinical development services to innovative pharmaceutical, biotechnology, generic drug and medical device companies, today announced that the United States Securities and Exchange Commission (SEC) has notified the Company that it has completed a two and half year investigation of the Company related to revenue recognition, earnings, company operations and related party transactions and does not intend to recommend any enforcement action by the Commission. The investigation, which is now closed, was originally initiated as an informal investigation in 2006 and became formal in March 2007.

"We are very pleased that the SEC has concluded its investigation of the Company and is recommending that no action be taken by the Commission," commented Jeffrey P. McMullen, president and CEO, PharmaNet Development Group, Inc. "This very favorable outcome now allows us to put this matter behind us."

About PharmaNet Development Group, Inc.

PharmaNet Development Group, Inc., a global drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug and medical device industries. The Company offers early and late stage consulting, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs. With approximately 2,300 employees and 40 facilities throughout the world, PharmaNet is a recognized leader in outsourced clinical development. For more information, please visit our website at www.pharmanet.com.

    Contact: Anne-Marie Hess
    Phone: (609) 951-6842
    E-mail: ahess@pharmanet.com

SOURCE PharmaNet Development Group, Inc.


'/>"/>
SOURCE PharmaNet Development Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. PharmAbcine Closes USD $6 Million Series A Financing
2. WaferGen Closes on Private Financings of Approx. $6.2 Million
3. Helix BioPharma Closes Private Placement
4. Alimera Sciences Closes $5 Million in Extended Series C Financing
5. Jennerex Closes $5 Million First Tranche of Series C Financing
6. Micromet Closes $80.5 Million Public Offering of Common Stock
7. PharmAthene, Inc. Closes on $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants
8. Signostics Closes Follow-On Financing of US$4 Million, Expands Board of Directors
9. NewLink Genetics Corporation Closes $7.5 Million Financing
10. Pharmaxis Closes Share Purchase Plan
11. China Biologic Products Closes the $9.6 Million Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... , ... June 23, 2016 , ... STACS DNA Inc., ... Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field ... DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... & Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... Review , the peer-reviewed journal from touchONCOLOGY, ... the escalating cost of cancer care is placing ... a result of expensive biologic therapies. With the ...
Breaking Biology Technology:
(Date:4/26/2016)... April 27, 2016 Research ... Multi-modal Biometrics Market 2016-2020"  report to their offering.  ... The analysts forecast the global multimodal ... 15.49% during the period 2016-2020.  Multimodal ... sectors such as the healthcare, BFSI, transportation, automotive, ...
(Date:4/13/2016)... 13, 2016  IMPOWER physicians supporting Medicaid patients in ... new clinical standard in telehealth thanks to a new ... higi platform, IMPOWER patients can routinely track key health ... mass index, and, when they opt in, share them ... to a local retail location at no cost. By ...
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
Breaking Biology News(10 mins):